BTIG Rates Evolus (EOLS) buy, $13 Price Target

BTIG maintains its buy stance on Evolus with a $13 price target, a 97.27% upside from the current price.

By TradeTexts Research Desk · Published Jun 18, 2026, 3:02 AM EDT · Updated Jun 23, 2026, 10:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

BTIG rated Evolus, Inc. ($EOLS) "buy" with a $13 price target on June 17, 2026.

Since the rating, $EOLS is up 3.4% after 1 week, down 15.0% after 1 month and up 5.3% to date (from the $6.74 close on Jun 17, 2026).

EOLS Evolus, Inc.

$7.10 +5.65% year to date

Daily close · Oct 16, 2026

Key Points

BTIG reiterated its buy rating for Evolus, Inc. (EOLS) on June 17, 2026, with a price target of $13.
BTIG's $13 price target implies 97.27% upside from Evolus, Inc.'s ($EOLS) current $6.59 share price.
Evolus shares are trading at $6.63, with a 52-week range between $3.86 and $10.2, and a market cap of $443.9 million.
CEO David Moatazedi sold shares in March 2026, and insider transactions were part of planned sales.

Get $EOLS trade alerts by text

We text you when insiders, Congress or big funds trade $EOLS. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Evolus, Inc. alert may contain errors. Disclosures

BTIG reiterated its buy rating on Evolus, Inc. (NasdaqGM: EOLS) on June 17, 2026. The firm set a price target of $13, suggesting confidence in the company's future performance. Evolus shares are currently trading at $6.63.

Analysts Set New Price Targets

On June 17, 2026, BTIG reiterated its buy rating on Evolus, Inc., maintaining a price target of $13. This aligns with previous ratings, as HC Wainwright & Co. also reiterated a buy rating with a $13 target earlier this year on February 3. Stifel maintained its buy rating with a slightly higher target of $17 on January 13. The consensus among analysts is strong, with a mean price target of $14.67 and a strong buy recommendation from six analysts.

Other Institutional Activity in Evolus

Nantahala Capital Management, LLC increased its holdings in Evolus by 556,208 shares, ending with 6,376,857 shares valued at approximately $26.2 million. BlackRock, Inc. also boosted its position by 195,083 shares to a total of 4,290,383 shares worth about $17.6 million. Meanwhile, Vanguard Capital Management LLC established a position with 2,470,408 shares valued at $10.2 million.

Evolus, Inc. Stock Down 16.2%

Shares of Evolus, Inc. (NasdaqGM: EOLS) are trading at $6.63. The company has a market capitalization of around $443.9 million and a forward P/E ratio of 25.27. With a beta of 1.334, Evolus has shown some volatility. The stock's 52-week low is $3.86, and its high is $10.2. Its 50-day moving average is $5.88, and the 200-day moving average is $5.91. Evolus maintains a current ratio of 2.04 and a quick ratio of 1.5.

12-month forecast

$EOLS price target

Evolus, Inc. daily closes and this analyst's $13 target. Not advice.

Recent Earnings

Evolus reported revenue of $301.8 million with a growth rate of 6.7%. Despite the revenue increase, the company posted a net margin of -14.39%, reflecting ongoing challenges in achieving profitability. The company is expected to announce its next earnings on August 4, 2026.

Insider Buying and Selling at Evolus, Inc.

In March 2026, CEO David Moatazedi sold 13,669 shares at an average price of $4.75 as part of a planned transaction. Additionally, Chief Medical Officer Rui Avelar sold 3,119 shares at the same price. On March 17, Moatazedi and Avelar executed planned sales of 116,720 and 29,996 shares, respectively, at $4.89 each.

About Evolus, Inc.

Evolus, Inc. is a healthcare company based in Newport Beach, California. It focuses on performance beauty products, targeting the cash-pay aesthetic market in the U.S., Canada, Europe, and Australia. The company offers Jeuveau, a botulinum toxin type A formulation for improving the appearance of glabellar lines, and Evolysse, a line of injectable hyaluronic acid gels. Led by CEO David Moatazedi, Evolus employs about 350 people.

Bottom Line

BTIG's reiteration of a buy rating for Evolus, Inc. with a $13 target reflects ongoing confidence in the company's potential. Investors watch Evolus closely for its position in the aesthetic market, despite its current unprofitability. This analyst update provides a snapshot of sentiment but remember, 13F filings and analyst ratings are backward-looking and may not reflect the latest positions or market conditions.